DAFNA Capital Management
DAFNA Capital Management reported 88 stocks worth $524M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RVMD (20.1%), XBI (5.9%) and CMPS (5.4%). Compared with Q1 2026, the fund opened new positions in ASND, KYMR and ANL, added to NKTR, DNLI and IDYA, trimmed RVMD, XBI and CMPS and sold out of ASND, FULC and SCYX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  RVMD Revolution Medicines Inc | $105M | 20.1% | 563K | −18K (−3%) | 8 of 8 | |
| 2 |  XBI Spdr Series Trust | $31.1M | 5.9% | 197K | −122K (−38%) | 8 of 8 | |
| 3 |  CMPS Compass Pathways PLC | $28.5M | 5.4% | 2M | −407K (−17%) | 8 of 8 | |
| 4 |  STXS Stereotaxis Inc | $23.5M | 4.5% | 13.7M | No change | 8 of 8 | |
| 5 |  NKTR Nektar Therapeutics | $22.2M | 4.2% | 318K | +153K (+93%) | 5 of 8 | |
| 6 |  DNLI Denali Therapeutics Inc | $19M | 3.6% | 739K | +421K (+132%) | 6 of 8 | |
| 7 |  IDYA Ideaya Biosciences Inc | $18.5M | 3.5% | 497K | +21K (+4%) | 8 of 8 | |
| 8 |  ATRC Atricure Inc | $16.7M | 3.2% | 597K | No change | 8 of 8 | |
| 9 |  XENE Xenon Pharmaceuticals Inc | $15.1M | 2.9% | 251K | No change | 8 of 8 | |
| 10 |  CYTK Cytokinetics Inc | $14.7M | 2.8% | 172K | −45K (−21%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
DAY ONE BIOPHARMACEUTICALS I | $21M | 978K |
KALVISTA PHARMACEUTICALS INC | $5.4M | 267K |
 ASND Ascendis Pharma A/s | $5.3M | 23K |
 FULC Fulcrum Therapeutics Inc | $1.6M | 205K |
ENGENE HOLDINGS INC | $1.3M | 187K |
🔒 Free account: see all 11.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →DAFNA Capital Management 13F FAQ
What does DAFNA Capital Management own?
DAFNA Capital Management reported 88 stocks worth $524M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RVMD (20.1%), XBI (5.9%) and CMPS (5.4%). The table above lists every position in the filing (the top 10 without an account).
What did DAFNA Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 17 new positions, 17 added to, 26 trimmed and 11 sold out. New positions include ASND, KYMR and ANL. It sold all of ASND, FULC and SCYX.
When will DAFNA Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is DAFNA Capital Management's portfolio worth?
The Q2 2026 filing reports $524M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.